ArticleThe Journal of infectious diseases2026
Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Cost-Effective Threshold Price for Alternative Infant and Neonatal Rotavirus Vaccines: A Dual-Country Evaluation.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGhana introduced the Rotarix vaccine in April 2012 and switched to the Rotavac vaccine in January 2020. Evaluating the health impact of this change is essential for national policy and can inform decisions in other countries.
methodsWe applied a previously validated mathematical model of rotavirus transmission in Navrongo, Ghana, to quantify the health impact of switching from Rotarix to Rotavac among children under 2. We first simulated the model from January 2007 to December 2019 using previously estimated model parameters from pre- and post-Rotarix surveillance data. We then refitted the model to data from January 2020 to March 2023 to estimate Rotavac vaccine effectiveness parameters. To assess overall vaccine effectiveness (OVE), we compared model simulations under the 2 vaccination scenarios (Rotarix and Rotavac) with a counterfactual scenario assuming no vaccination.
resultsThe model accurately captured both the trend and seasonality of postvaccination rotavirus cases, with a Spearman correlation of 0.70. Compared to the no-vaccination scenario, the estimated OVE against moderate-to-severe rotavirus cases was 21.7% (95% prediction interval [PI]: 17.4%-26.1%) in children under 2 years in Navrongo. Annual OVE ranged from 8.4% (PI: 1.0%-21.0%) to 63.5% (PI: 39.0%-87.0%). Following the switch from Rotarix to Rotavac (2020-2023), we estimated a mean relative OVE of 37.1% (PI: 27.5%-46.5%).
conclusionsOur model offers a robust tool to support policymakers in Ghana and similar settings by evaluating current rotavirus vaccine effectiveness, guiding vaccine switching decisions and informing introduction strategies in countries yet to adopt immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.